| Entry |
|
|---|
| Name |
Brivanib (USAN) |
|---|
| Formula |
C19H19FN4O3
|
|---|
| Exact mass |
370.1441
|
|---|
| Mol weight |
370.38
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
|
|---|
| Remark |
|
|---|
| Efficacy |
Antineoplastic, Angiogenesis inhibitor, Receptor tyrosine kinase inhibitor |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Brite |
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG01373 Brivanib
D09589 Brivanib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
FGFR family
FGFR1 (CD331)
D09589 Brivanib (USAN)
VEGFR family
VEGFR2 (KDR)
D09589 Brivanib (USAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG01373 Brivanib
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 27
1 C8y C 20.0343 -24.4505
2 C8y C 20.0343 -25.8516
3 C8x C 21.2477 -26.5522
4 C8x C 22.4612 -25.8516
5 C8y C 22.4612 -24.4505
6 C8y C 21.2477 -23.7499
7 C8x C 18.7017 -24.0175
8 C8y C 17.8781 -25.1511
9 N4x N 18.7017 -26.2846
10 X F 21.2477 -22.3489
11 O2a O 23.6934 -23.7389
12 C8y C 23.6931 -22.3488
13 C8y C 24.8946 -21.6547
14 N4y N 24.8943 -20.2535
15 N5x N 23.6807 -19.5532
16 C8x C 22.4792 -20.2473
17 N5x N 22.4795 -21.6485
18 C8y C 26.2273 -22.0874
19 C8y C 27.0506 -20.9536
20 C8x C 26.2268 -19.8201
21 O2a O 28.4414 -20.9532
22 C1b C 29.1441 -19.7353
23 C1c C 30.5430 -19.7349
24 O1a O 31.2534 -20.9643
25 C1a C 31.2341 -18.5375
26 C1a C 26.6520 -23.3946
27 C1a C 16.4613 -25.1511
BOND 30
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 1 7 1
8 7 8 2
9 8 9 1
10 2 9 1
11 6 10 1
12 5 11 1
13 11 12 1
14 12 13 1
15 13 14 1
16 14 15 1
17 15 16 2
18 16 17 1
19 12 17 2
20 13 18 2
21 18 19 1
22 19 20 2
23 14 20 1
24 19 21 1
25 21 22 1
26 22 23 1
27 23 24 1
28 23 25 1 #Up
29 18 26 1
30 8 27 1
|
|---|
